Ligand ID: 2GM Drugbank ID: DB00320(Dihydroergotamine) Indication:For the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.68A | 16.38 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.69A | 20.89 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.68A | 20.66 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | THR D 225VAL D 202SER D 267ASP D 248 | 1.77A | 20.84 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 6 | THR B 26VAL B 73SER B 121ASP B 92 | 1.69A | 20.84 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 86THR A 85VAL A 204ASP A 208 | 1.65A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | ASP A 274VAL A 353TRP A 268PHE A 321LEU B 117 | 1.78A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 234ASP A 36 | 1.77A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 184VAL B 159PHE B 147LEU A 388THR B 141 | 1.74A | 18.41 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 148VAL A 128ASP A 208 | 1.59A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 12ALA A 443TRP C 29MET C 52LEU C 60 | 1.67A | 12.70 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 204ASP A 208 | 1.69A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 5 / 12 | CYH A 842VAL A 848ALA A 840PHE A 859LEU A 895 | 1.76A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 141VAL A 174ASP A 155 | 1.70A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6vsb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU B 948ALA B1020MET B1029LEU B1063PHE B1062 | 1.70A | 16.16 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6vxx | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | VAL C1061ALA C 871PHE C 782MET C1029LEU C1024 | 1.61A | 16.15 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6vyb | SPIKE GLYCOPROTEIN (SARS-CoV-2) | 5 / 12 | LEU A 948ALA A1020MET A1029LEU A1063PHE A1062 | 1.63A | 16.15 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w41 | CR3022 FAB HEAVYCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 4 / 6 | THR H 31VAL C 395SER C 383ASP C 398 | 1.78A | 14.80 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | ILE A6910THR A6908SER A7090ASP A6931 | 1.45A | NoneNoneNoneEDO A7102 (-4.6A) | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.68A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL C6894LEU C6959PHE C6954THR C6918 | 1.77A | 17.46 | NoneNoneNoneNoneFMT C7113 ( 4.8A) | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU C6892VAL C6894ALA C6919PHE C6954PHE C6868 | 1.65A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | ILE A6910THR A6908SER A7090ASP A6931 | 1.56A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | TRP A6922THR A6915SER C7089ASP A6906 | 1.52A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | TRP A6922VAL C7094SER C7090ASP A6895 | 1.73A | 17.46 | NoneNone NA C7104 ( 2.5A)None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 5 / 12 | LEU A6892VAL A6894ALA A6919PHE A6954PHE A6868 | 1.77A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | THR C6915VAL C7086SER A7089ASP C6906 | 1.74A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | ILE C6910THR C6908SER C7090ASP C6931 | 1.47A | 17.46 | NoneNone NA C7104 ( 2.5A)None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | TRP C6922THR C6915SER A7089ASP C6906 | 1.57A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 6 | TRP A6922VAL C7094SER C7089ASP A6895 | 1.77A | 17.46 | None | ||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | ALA B 139PHE B 127PHE B 147MET B 169PHE B 173 | 1.80A | 21.84 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wiq | NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.62A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | TRP A6922THR A6915SER C7089ASP A6906 | 1.53A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | TRP C6922THR C6915SER A7089ASP C6906 | 1.59A | NoneFMT C7107 (-3.7A)NoneNone | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | ILE C6910THR C6908SER C7090ASP C6931 | 1.49A | NoneNoneFMT C7107 (-2.7A)None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | ILE A6910THR A6908SER A7090ASP A6931 | 1.58A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | TRP A6922VAL C7094SER C7089ASP A6895 | 1.72A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | TRP A6922VAL C7094SER C7090ASP A6895 | 1.70A | NoneNoneFMT C7107 (-2.7A)None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | THR C6915VAL C7086SER A7089ASP C6906 | 1.77A | FMT C7107 (-3.7A)NoneNoneNone | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | ILE A6910THR A6908SER A7090ASP A6931 | 1.58A | NoneNone NA A7102 ( 3.2A)None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | THR C6915VAL C7086SER A7089ASP C6906 | 1.75A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | TRP A6922THR A6915SER C7089ASP A6906 | 1.52A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | TRP C6922THR C6915SER A7089ASP C6906 | 1.59A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 6 | ILE C6910THR C6908SER C7090ASP C6931 | 1.47A | NoneNone NA C7102 ( 2.7A)None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | ILE A 323THR A 326VAL A 295ASP A 268 | 1.73A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | ILE B 72THR B 275VAL B 67SER B 198 | 1.58A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | ILE A 72THR A 275VAL A 67SER A 198 | 1.61A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wlc | URIDYLATE-SPECIFICENDORIBONUCLEASE (SARS-CoV-2) | 4 / 6 | ILE B 323THR B 326VAL B 295ASP B 268 | 1.76A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.76A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 6 | ILE A6910THR A6908SER A7090ASP A6931 | 1.48A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.63A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6wqd | NSP8 (SARS-CoV-2) | 4 / 6 | ILE D 156THR D 145VAL D 131ASP D 134 | 1.65A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | ILE D 156THR D 145VAL D 131ASP D 134 | 1.53A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.55A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yla | HEAVY CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 6 | ILE E 434THR H 31VAL E 341SER E 371 | 1.80A | NoneNoneNoneDMS E 901 ( 4.4A) | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6ym0 | HEAVY CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 6 | ILE E 434THR H 31VAL E 341SER E 371 | 1.75A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.72A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yor | IGG H CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 6 | ILE E 434THR H 31VAL E 341SER E 371 | 1.80A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yor | IGG H CHAINSPIKE GLYCOPROTEIN (Homosapiens;SARS-CoV-2) | 4 / 6 | ILE A 434THR B 31VAL A 341SER A 371 | 1.80A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | LEU A 167VAL A 171PHE A 112LEU A 141PHE A 140 | 1.79A | 20.84 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 86THR A 85VAL A 204ASP A 208 | 1.62A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.63A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | CYH A 842VAL A 848ALA A 840PHE A 859LEU A 895 | 1.74A | 17.83 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | THR A 393VAL B 186SER A 397ASP B 161 | 1.73A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 148VAL A 128ASP A 208 | 1.57A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12NSP7NSP8 (SARS-CoV-2) | 4 / 6 | THR A 409VAL B 131SER C 26ASP A 454 | 1.68A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | THR B 84VAL A 342SER A 367ASP B 99 | 1.59A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 204ASP A 208 | 1.71A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 837VAL A 844SER A 861ASP A 418 | 1.77A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7btf | NSP8 (SARS-CoV-2) | 4 / 6 | ILE D 156THR D 145VAL D 131ASP D 134 | 1.59A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 6 | THR A 26VAL A 73SER A 121ASP A 92 | 1.67A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 119THR A 324VAL A 341ASP A 377 | 1.67A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | THR A 531VAL A 495SER A 564ASP A 517 | 1.76A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 86VAL A 204ASP A 208 | 1.33A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 148VAL A 128ASP A 208 | 1.40A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 184VAL B 159PHE B 147LEU A 388THR B 141 | 1.78A | 17.87 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 589THR A 591VAL A 693ASP A 481 | 1.46A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 233ASP A 36 | 1.76A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.61A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 204ASP A 208 | 1.67A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 5 / 12 | CYH A 842VAL A 848ALA A 840PHE A 859LEU A 895 | 1.71A | 17.68 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 120THR B 124VAL A 342SER A 384 | 1.47A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12NSP7NSP8 (SARS-CoV-2) | 4 / 6 | THR A 409VAL B 131SER C 26ASP A 454 | 1.70A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 86VAL A 204ASP A 36 | 1.80A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12NSP7 (SARS-CoV-2) | 5 / 12 | VAL C 12ALA A 443TRP C 29MET C 52LEU C 60 | 1.79A | 11.20 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 837VAL A 844SER A 861ASP A 418 | 1.71A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 141VAL A 174ASP A 155 | 1.73A | None | |||
![]() | 4IAQ_A_2GMA2001_1 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | LEU B 184VAL B 159PHE B 147LEU A 388THR B 141 | 1.73A | 17.87 | None | ||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP8 (SARS-CoV-2) | 4 / 6 | ILE B 156THR B 145VAL B 131ASP B 134 | 1.65A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 148VAL A 128ASP A 208 | 1.58A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | THR A 531VAL A 495SER A 564ASP A 517 | 1.67A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 86THR A 85VAL A 204ASP A 208 | 1.35A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 589THR A 591VAL A 693ASP A 481 | 1.61A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 234ASP A 36 | 1.77A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | TRP A 216ILE A 201VAL A 204ASP A 208 | 1.75A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 6 | ILE A 145THR A 141VAL A 174ASP A 155 | 1.65A | None | |||
![]() | 4IAQ_A_2GMA2001_2 (CHIMERA PROTEIN OFHUMAN5-HYDROXYTRYPTAMINERECEPTOR 1B AND E.COLI SOLUBLECYTOCHROME B562) | 7bv2 | NSP12NSP8 (SARS-CoV-2) | 4 / 6 | ILE A 333THR A 344VAL A 338ASP B 101 | 1.63A | None |